AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
AZN Chart
Similar
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS, driving an increase to its price target and reiterated 'buy' rating. Analyst Matthew Weston said the company and the wider sector face a "significant patent cliff" around 2030-and-beyond but argues the FTSE 100 drugmaker is well positioned to manage this with "sector leading replacement power".
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', citing a less favourable earnings trajectory as the drugmaker prioritises revenue growth through escalating research spending. The broker warns the current valuation looks full at 20 times forecast 2026 earnings despite confidence the company can exceed its $80 billion 2030 revenue target.
AstraZeneca PLC American Depositary Shares (AZN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has AstraZeneca PLC American Depositary Shares ever had a stock split?
AstraZeneca PLC American Depositary Shares Profile
| Pharmaceuticals Industry | Healthcare Sector | Pascal Claude Roland Soriot CEO | NASDAQ (NGS) Exchange | 046353108 CUSIP |
| GB Country | 94,300 Employees | 8 Aug 2025 Last Dividend | 27 Jul 2015 Last Split | - IPO Date |
Overview
AstraZeneca PLC, established as Zeneca Group PLC before its name change in April 1999, is a biopharmaceutical entity recognized for its deep involvement in the health sector. Since its incorporation in 1992, the company has centered its prowess on the discovery, development, management, and commercialization of prescription medicines. Holding its headquarters in Cambridge, United Kingdom, AstraZeneca has expanded its reach globally, touching the markets of the United Kingdom, the Americas, Europe, Asia, Africa, and Australasia. Through a network of distributors and local representative offices, it caters to the essential needs of both primary care and specialty care physicians. Furthermore, AstraZeneca upholds strategic collaboration agreements, such as with Neurimmune AG for the development of NI006, and with BenevolentAI targeting drug discovery in systemic lupus erythematosus, underlining its commitment to healthcare innovation and partnerships to tackle diverse health challenges.
Products and Services
Cardiovascular, Renal, and Metabolism Products: AstraZeneca offers a range of medicines including Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, and Farxiga, designed to address various health concerns within cardiovascular, renal, and metabolic diseases. These pharmaceuticals represent the company's focus on developing treatments that aim to improve patient outcomes in these critical areas of medicine.
Oncology: The company's oncology segment features drugs like Orpathys, Truqap, Zoladex, Faslodex, enhancing its footing in the field with innovative solutions for cancer treatment and management, showcasing AstraZeneca's significant contributions to advancing cancer care.
Respiratory and Immunology: Products such as Fasenra, Breztri, Symbicort, Saphnelo, and Tezspire cater to a wide range of respiratory conditions, including COPD and asthma, emphasizing AstraZeneca's role in developing drugs that significantly improve the lives of people living with these conditions.
Covid-19 and Rare Diseases: The development and provision of Vaxzevria and Beyfortus for Covid-19, alongside Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for various rare diseases, reflect AstraZeneca's flexible approach towards global health crises and its dedication to addressing less common but equally critical health challenges.
Partnerships for Drug Development: AstraZeneca's collaborative efforts, such as with Neurimmune AG for the development of NI006 and BenevolentAI for drug discovery in systemic lupus erythematosus, highlight its strategy to leverage external expertise and technology to broaden its research and development capabilities, aiming to deliver innovative therapeutic options to patients faster.
